DUBLIN, April 19, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:30 p.m. ET/9:30 p.m. IST to discuss first quarter 2021 financial results and provide a business and financial update.
Audio webcast/conference call: U.S. Dial-In Number: +1 855 353 7924 International Dial-In Number: +1 503 343 6056 Passcode: 8765706
A replay of the conference call will be available through May 11, 2021:
Replay U.S. Dial-In Number: +1 855 859 2056 Replay International Dial-In Number: +1 404 537 3406 Passcode: 8765706
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. A replay of the webcast will be archived on the website for at least one week.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Jazz Pharmaceuticals Contacts:
Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations U.S. +1 561 306 4035
Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Ireland +353 1 697 2141 U.S. +1 215 867 4910